In April 2009, VITAL-NET, INC. (based in Tohoku and Niigata) and KSK Co., Ltd. (based in six prefectures in the Kansai region) merged through a share transfer to establish the joint holding company VITAL KSK HOLDINGS, INC.

The two companies—both in the wholesale pharmaceutical industry—aim to achieve sustainable growth and improved corporate value by sharing and developing the expertise that was cultivated individually as regional wholesalers.

We will evolve quickly by identifying and responding to changing times.

April 2009 Company established
Ken Suzuki appointed as first president
April 2009 Listed on Tokyo Stock Exchange 1st Section
November 2009 Began operations of Kyoto Logistics Center [KSK]
April 2010 Established VK Shared Service Co., Ltd. to integrate head office roles
January 2014 Acquired Finese Co., Ltd. as an equity method affiliated company
July 2014 Made pharmacy chain OHNO CO. LTD. a consolidated subsidiary
March 2015 Began operations of Miyagi Logistics Center [VITAL-NET]
June 2015 Taisuke Murai appointed as president
April 2017 Acquired VK Shared Service Co., Ltd. by an absorption merger
May 2018 Began operation of Hyogo Logistics Center [KSK]
Established Safuran Kids, a corporate-led childcare facility [VITAL-NET]
July 2018 Established Reed Specialties, Inc. as an equity method affiliated company
September 2018 Signed capital and business partnership agreement with SanBio Co, Ltd.
May 2019 Opened Sendai Robocare Center [VITAL-NET]
April 2020 Made pharmacy chain Goodneighbor Inc. a consolidated subsidiary
September 2020 Began operations of Kawaguchi Logistics Center [VITAL-NET]
April 2021 Made pharmacy chain Kenkodo Pharmacy Co., Ltd. a consolidated subsidiary
April 2022 Moved to Tokyo Stock Exchange Prime Market
April 2022 Start of the fifth Medium-Term Management Plan
April 2023 Formulated Long-Term Vision 2035
June 2023 Transition to a company with an Audit & Supervisory Committee
February 2024 Participated in LinDo K.K.’s new business model for eliminating “drug loss” (unrecognized overseas drug approval)